drugset
drugset / Trial / NCT00887861

Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery

NCT00887861 ↗

Phase 2 Completed 37 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.

Timeline

Start
2009-03
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject selurampanel Small molecule — —

Indications

epilepsy